FEP Multi-Channel Distillation Column Packing
Solvent recycling saves money and is good for the environment. Using our PFE column packing, solvents can be efficiently recovered and reused, reducing environmental burden and spent solvent disposal costs. With the proper column height, solvents can be restored to their original purity or better.
The packing’s unique geometric shape was developed in our chemical R&D laboratories for the purification of deuterated solvents and solvent recovery. Liquid does not pool irregardless of packing orientation. The surface is completely inert to polar and non-polar solvents, acids and bases, thereby eliminating any possible metal, organo-metalic, or monomer contamination as when using other packing materials. Due to the inert nature of PFE, cleaning and drying the packing for later use is easy and straight forward.
As an example of its distillation efficiency, we were able to produce 99.9% atom D2O from water using regular types of distillation columns and receivers. We have also distilled organic solvents to 99.99% purity and have recycled these for our own use. If you are interested in solvent recovery, whether for HPLC, HPLC-NMR, wet chemistry or other use, Norell’s PFE column packing is the leading product of choice.
http://www.nmrtubes.com/
Nine U.S. Health Research Centers to Receive $255 Million
Nine health research centers have received funds to develop ways to reduce the time it takes for clinical research to become treatments for patients. The funds were awarded as part of the Clinical and Translational Science Awards (CTSA) program which is led by the National Center for Research Resources (NCRR), part of the National Institutes of Health.
“A critical goal of biomedical research is to transform discoveries into preventions, treatments, and cures,” said NIH Director Francis S. Collins, M.D., Ph.D. “By working together, CTSAs are removing barriers to research, training new generations of clinical and laboratory research teams, and providing them with the equipment and resources they need.”
Now in its fourth year, the CTSA consortium has generated resources that transform the research and training environment to enhance the efficiency and quality of clinical and translational research. Examples include a Web-based national recruitment registry that connects researchers with volunteers interested in participating in clinical studies, establishing public-private partnerships, and a portal that connects researchers with potential investigational drugs that may be useful in new ways.
The 2010 CTSAs expand consortium representation in new areas including New Mexico, Virginia and the District of Columbia, growing the consortium to 55 member institutions. The nine new institutions are:
Children’s National Medical Center, Washington, D.C.
Georgetown University with Howard University, Washington, D.C.
Medical College of Wisconsin, Milwaukee
University of California, Irvine
University of California, San Diego
University of Massachusetts, Worcester
University of New Mexico Health Sciences Center, Albuquerque
University of Southern California, Los Angeles
Virginia Commonwealth University, Richmond
View descriptions of these CTSA awardees at www.ncrr.nih.gov/ctsa2010.
“The nine institutions that have received CTSAs this year extend the geographic reach of the consortium and bring additional talent and expertise in such areas as children’s health, outreach to underrepresented communities, and systems to share research information,” said NCRR Director Barbara Alving, M.D.
The CTSA consortium now includes awardees in 28 states and the District of Columbia. When the program is fully implemented in 2011, it will support approximately 60 CTSAs across the nation.
A sixth and final funding opportunity announcement for CTSAs is available, calling for the next round of applications to be submitted by Oct. 14, 2010, with the awards expected in July 2011. For more information about this funding announcement, see www.ncrr.nih.gov/crfunding.
For more information about the CTSA program, visit www.ncrr.nih.gov/ctsa. The CTSA consortium website, which provides information on the consortium, current members and new grantees, can be accessed at www.CTSAweb.org.
The National Center for Research Resources (NCRR), a part of NIH, provides laboratory scientists and clinical researchers with the resources and training they need to understand, detect, treat and prevent a wide range of diseases. NCRR supports all aspects of translational and clinical research, connecting researchers, patients and communities across the nation. For more information, visit www.ncrr.nih.gov.
The National Institutes of Health (NIH) — The Nation’s Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
Alfa Aesar Now Offers Homopiperazines
Alfa Aesar, a Johnson Matthey Company, has entered into a distribution agreement with Tosoh Organic Chemical Co. Ltd., a recognized world leader in the development and production of unique organic chemical intermediates.
Alfa Aesar is the sole distributor of research and development quantities of substituted homopiperazine products from Tosoh. Substituted homopiperazines have shown promise in drug discovery as intermediates in the production of compounds suitable for the generation of diverse combinatorial libraries. The select products are in stock and are available for immediate shipment. This technology can be applied to a wide variety of related materials; if there are additional compounds of interest please feel free to contact Alfa Aesar for further discussion.
Homopiperazines
- H51685
1-(2-Methylphenyl)homopiperazine monohydrochloride, 98% - H51686
1-(3-Fluorophenyl)homopiperazine monohydrochloride, 98% - H51687
1-(4-tert-Butoxyphenyl)homopiperazine monohydrochloride, 98% - H51700
1-(3-Methylphenyl)homopiperazine monohydrochloride, 98% - H51701
1-(4-Fluorophenyl)homopiperazine dihydrochloride, 98% - H51702
1-(4-tert-Butylphenyl)homopiperazine dihydrochloride, 98% - H51703
1-(4-Methoxyphenyl)homopiperazine monohydrochloride, 98% - H51750
1-(4-Methylphenyl)homopiperazine monohydrochloride, 98% - H51751
1-(3-Methoxyphenyl)homopiperazine monohydrochloride, 98% - H51752
1-(3-tert-Butoxyphenyl)homopiperazine monohydrochloride, 98%
TimTec Contract Research Services
TimTec brings 15 years of expertise in organic chemistry design and supply for drug discovery closer to your supplemental bench-top requirements by launching The Organic Synthesis and Medicinal Chemistry Contract Research Services Division. TimTec scientists have a proven track record of providing high quality services and showing outstanding integrity to their clients.
TimTec remains flexible in delivering practical chemistry solutions molded to custom research requirements and budgets. All Contract Research Services are delivered with an emphasis on speed, real-time feedback, ongoing communication, superior compound quality, and the protection of our clients’ knowledge resources and interests. We are dedicated to providing these services at exceptionally competitive prices.
The Head of Contract Research Services has over 20 years of research experience in the US pharmaceutical industry as a hands-on medicinal chemist and project Team Leader at large companies and smaller, start-up operations. We are keenly aware of all the intricate details and chemistry challenges that go into bench-top research before a qualified lead molecule emerges. Your TimTec contract research team consists of experienced, bench level scientists who have access to state of the art synthesis, analytical and quality control facilities.
TimTec Contract Research Services Start with:
-
Flexible Contracts
-
Program Management
-
State of the Art Facilities
-
Structure-Activity Relationship Evaluation
-
Lead Optimization
-
Property Optimization for ADME and PK
-
Metabolite Synthesis
-
Enabling Technologies – Parallel synthesis, multistep synthesis, analytical chemistry
-
Mg to Kg Capacity
-
Compound Distribution – Solid or solution, vials or plates
-
Patent Application Preparation Assistance
Supplemental Services and Products:
HTS compounds and compound collections – ActiMol Line of products
Neuronetrix’ COGNISION™ System
Alzheimer’s disease is a chronic neurodegenerative disease of the brain which afflicts roughly 5 million individuals in the United States. Approximately 10% of those over 65 and 50% of those over 85 will die as a result of Alzheimer’s disease.
Even with several therapies available to treat Alzheimer’s disease, there still is a significant gap between the onset of the disease and point at which treatment actually begins. This treatment gap is directly tied to the challenges in diagnosing the disease early, before the significant loss of memory, cognition, and activities of daily living. Patients, doctors, caregivers, and the pharmaceutical industry, are looking for and demanding a solution to this problem.
Neuronetrix’ COGNISION™ System will, for the first time, directly detect the abnormal cognitive effects of Alzheimer’s disease! This will facilitate an earlier and more accurate diagnosis than is currently available. Physicians will use the COGNISION™ test to determine which patients would benefit from the available drug treatments. The system can also be used to monitor the efficacy of the prescribed therapy.
With the aging of America and the proliferation of new Alzheimer’s therapies, the market for Alzheimer’s screening could approach several billion dollars per year in the United States alone.
Following the validation of the COGNISION™ System for Alzheimer’s disease, Neuronetrix will expand into other neurodiagnostic markets such as ADHD, dyslexia, and depression.
http://www.neuronetrix.com/